‘Smart’ hydrogel for the radiosensitization and sustained delivery of therapeutics triggered by irradiation

Patent metadata

Field	Value
Publication number	US-12486401-B2
Application number	US-202017593982-A
Country	US
Kind code	B2
Filing date	Mar 30, 2020
Priority date	Mar 31, 2019
Publication date	Dec 2, 2025
Grant date	Dec 2, 2025

Abstract

The present invention provides a hydrogel for comprising a biodegradable polyphosphazene polymer, a radiation-sensitive diselenide cross-linker; and one or more payloads releasably loaded within the hydrogel. The present invention further provides methods for radiosensitizing target tissues such as tumors and providing sustained delivery of therapeutics triggered by irradiation. In another aspect, the present invention provides a method that includes: introducing the hydrogel, as describes herein, adjacent to malignant or marginal tissue; and administering radiation to the hydrogel, thereby disrupting the selenocystamine cross-linkers and releasing the one or more payloads.

First claim

The invention claimed is:

1 . A hydrogel comprising:
a biodegradable polyphosphazene polymer a radiation-sensitive diselenide cross-linker; and one or more payloads releasably loaded within the hydrogel.

2 . The hydrogel of claim 1 , wherein the polyphosphazene comprises a polycarboxylate polymer.

3 . The hydrogel of claim 2 , wherein the polycarboxylate polymer comprises di(carboxylatophenoxy)phosphazene (PCPP).

4 . The hydrogel of claim 1 , wherein the radiation-sensitive cross-linker comprises one or more selected from the group consisting of: selenocystamine, 3,3′-diselenodipropionic acid, 4,4′-diselenodibutanoic acid, 5,5′-diselenodipentanoic acid, diselenium functionalized polyurethane, and diselenium functionalized dextran.

5 . The hydrogel of claim 1 wherein the radiation is one or more selected from the group consisting of: acoustic radiation, electromagnetic radiation and particle radiation.

6 . The hydrogel of claim 5 , wherein the electromagnetic radiation comprises X-ray radiation.

7 . The hydrogel of claim 5 , wherein the particle radiation comprises proton therapy or radioisotope decay.

8 . The hydrogel of claim 7 , wherein the radioisotope decay comprises cobalt-60 decay.

9 . The hydrogel of claim 5 , wherein the acoustic radiation comprises focused ultrasound radiation.

10 . The hydrogel of claim 1 , wherein the one or more payloads are selected from the group consisting of: nanoparticles and one or more chemotherapeutic agents.

11 . The hydrogel of claim 10 , wherein the nanoparticles are selected from the group consisting of: gold nanoparticles (AuNP) and silver sulfide nanoparticles (Ag 2 S NP), gadolinium nanoparticles, europium nanoparticles, bismuth nanoparticles, iron oxide-containing nanoparticles, silver nanoparticles, tantalum nanoparticles, ytterbium nanoparticles, tungsten nanoparticles, alloys including one or more thereof, compounds including one or more thereof, and any combinations thereof.

12 . The hydrogel of claim 10 , wherein the nanoparticles have a maximum cross-sectional dimension between about 1 nm and about 150 nm.

13 . The hydrogel of claim 10 , wherein the nanoparticles have a maximum cross-sectional dimension less than about 5 nm.

14 . The hydrogel of claim 10 , wherein the one or more chemotherapeutic agents are selected from the group consisting of: doxorubicin, quisinostat, carboplatin, cisplatin, paclitaxel, albumin-bound paclitaxel, docetaxel, gemcitabine, vinorelbine, irinotecan, etoposide, vinblastine, imiquimod, resiquimod, and pemetrexed.

15 . A method comprising:
introducing the hydrogel of claim 1 adjacent to malignant or marginal tissue; and administering radiation to the hydrogel, thereby disrupting the cross-linkers and releasing the one or more payloads.

16 . The method of claim 15 , wherein the hydrogel is introduced by injection or after resection of malignant tissue.

17 . The method of claim 15 , wherein radiation is one or more selected from the group consisting of: electromagnetic radiation and particle radiation.

18 . The method of claim 15 , wherein the radiation is administered after a period of time from the introduction of the hydrogel, the period of time being selected from the group consisting of: between 1 hour and 1 week, between 1 week and 2 weeks, between 2 weeks and 3 weeks, between 3 weeks and 4 weeks, between 4 weeks and 8 weeks, between 8 weeks and 12 weeks, between 12 weeks and 16 weeks, and greater than 16 weeks.

19 . The method of claim 15 , wherein:
the administering step is repeated a plurality of times; and the hydrogel releases a portion of the payload after each repetition.

20 . A hydrogel comprising:
di(carboxylatophenoxy)phosphazene (PCPP); a selenocystamine cross-linker; a gold nanoparticle (AuNP); and quisinostat.

Assignees

• Univ Pennsylvania

Inventors

• Bouché Mathilde
• Cormode David
• Sheikh Saad
• Dorsey Jay

Classifications

• C08L2312/06

  by radiation · CPC title

• C08L2201/06

  Biodegradable · CPC title

• C08G79/025

  Polyphosphazenes · CPC title

• A61K45/06

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title

• A61K41/0057

  Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent · CPC title